Daye, a London, UK-based gynaecological health startup which invented the CBD tampon, raised £10M in Series A funding.
Backers included Hambro Perks, MassMutual Ventures, and Cross Border Impact Ventures, Simplyhealth and UK medics Dr Michelle Tempest and Dr Fiona Pathiraja.
The company intends to use the funds to launch its tampon-based at-home vaginal microbiome screening kit, to roll out a digital platform for gynae health, and kickstart its launch in the U.S.
Funded by Valentina Milanova, Daye is a female-founded gynaecological health startup creating products and services for period pain, at-home STI testing, and the treatment of vaginal infections. The tampon-based at-home vaginal microbiome screening kit provides a way for women to test themselves at home. The kit is designed to test for vaginal infections, like thrush or bacterial vaginosis (BV), and disruptions to the microbiome, which could leave women prone to a higher risk of STIs, gynaecological cancers, and fertility and IVF complications. Daye will also roll out a comprehensive digital platform for gynae health, designed to reduce pain, shame and time wasted for women as they navigate their health journey from first period through to menopause.
Over 60,000 people have used its CBD tampon, which has achieved ISO 13485 certification, meaning it reaches the highest standards possible for medical devices.
Founded in 2017, Daye has raised nearly £19m to date, with other backers including Martin Varsavsky, founder of Prelude, the largest chain of fertility clinics in the world, and American venture capital firm Khosla Ventures.
FinSMEs
25/10/2022